Galapagos to be included in Amsterdam Midcap Index
March 06 2015 - 1:48AM
Galapagos NV (Euronext: GLPG) announces that Euronext will
include Galapagos in the Amsterdam Midcap Index, following
Euronext's annual review of the AEX®, AMX® and AScX® indices,
effective 23 March 2015.
About Galapagos Galapagos (Euronext:
GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule
medicines with novel modes of action, with a pipeline comprising
three Phase 2 programs, two Phase 1 trials, five pre-clinical
studies, and 25 discovery small-molecule and antibody programs in
cystic fibrosis, inflammation, and other indications. In the
field of inflammation, AbbVie and Galapagos signed a collaboration
agreement for the development and commercialization of
filgotinib. Filgotinib is an orally-available, selective
inhibitor of JAK1 for the treatment of rheumatoid arthritis and
potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. GLPG1205, a
first-in-class inhibitor of GPR84, is currently being tested in a
Phase 2 proof-of-concept trial in ulcerative colitis
patients. GLPG1690 is a compound that targets pulmonary
diseases and is currently in a Phase 1 trial. AbbVie and
Galapagos also signed a collaboration agreement in cystic fibrosis
to develop and commercialize molecules that address mutations in
the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1
trial, and corrector GLPG2222 is at the pre-clinical candidate
stage. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV Elizabeth Goodwin, Head of
Corporate Communications & IR Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements This release may
contain forward-looking statements, including, without limitation,
statements concerning the safety and efficacy of filgotinib and the
expected timing of the release of topline 12-week results from the
DARWIN 1 and 2 trials and the expected timing and announcement of
topline 24-week results from the DARWIN 1 and 2 trials,
expectations regarding the commercial potential of our product
candidates generally, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," "continues," "we believe," "we
intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future
results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements.
Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities, regulatory approval
requirements and estimating the commercial potential of our product
candidates. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
HUG#1899948
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024